Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma: Clinical Insights from a US Oncologists' Survey
A patient specific case scenario on advanced lung cancer in a situation involving a patient with EGFR Mutation Positive Adenocarcinoma that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals:
Treatment decisions for advanced stages of lung cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.
This report allows you to:
- Decisions in treatment and tests through disease stages
- Factors influencing their decisions
- Barriers to optimal patient care
- Confidence in treatment
Treatment decisions for advanced stages of lung cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.
This report allows you to:
- Understand what occurs with actual patients
- Access the most up-to-date prescribing trends
- Gain actionable data for developing and improving your market strategies
- Pinpoint needs of your target audience
- Focus resources to maximize the effectiveness of your budget
- Understand where your product fits
- Understand where your competitor’s product fits
- Design messages to advance brand performance
Executive Summary - US Oncologist Survey
Optimizing Treatment of Advanced Lung Cancer:
CHAPTER 1: INTRODUCTION
Table 1: Treatment Options in Advanced Lung Cancer
CHAPTER 2: RESPONDENT DEMOGRAPHICS
Table 2: Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years Since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by State’s Lung Cancer Mortality
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen
CHAPTER 3: TREATMENT OF AN EGFR MUTATION POSITIVE ADENOCARCINOMA
Figure 3.1 First line chemotherapy regimen
Figure 3.2 Factors influencing treatment decision
Figure 3.3 Confidence in treating patient to an optimal outcome
Figure 3.4 Sequence of treatment choices
Figure 3.5 Factors influencing treatment decision
Figure 3.6 Barriers to management of advanced lung cancer
CHAPTER 4: SUMMARY
APPENDIX A: SURVEY INSTRUMENT
Optimizing Treatment of Advanced Lung Cancer:
CHAPTER 1: INTRODUCTION
Table 1: Treatment Options in Advanced Lung Cancer
CHAPTER 2: RESPONDENT DEMOGRAPHICS
Table 2: Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years Since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by State’s Lung Cancer Mortality
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen
CHAPTER 3: TREATMENT OF AN EGFR MUTATION POSITIVE ADENOCARCINOMA
Figure 3.1 First line chemotherapy regimen
Figure 3.2 Factors influencing treatment decision
Figure 3.3 Confidence in treating patient to an optimal outcome
Figure 3.4 Sequence of treatment choices
Figure 3.5 Factors influencing treatment decision
Figure 3.6 Barriers to management of advanced lung cancer
CHAPTER 4: SUMMARY
APPENDIX A: SURVEY INSTRUMENT
